PLEKHA8 Antibody

What is PLEKHA8 and why is it significant in cellular research?

PLEKHA8 (Pleckstrin Homology Domain Containing, Family A Member 8) serves as a critical cargo transport protein in cellular trafficking systems. This protein is essential for apical transport from the Golgi complex and specifically transports AQP2 from the trans-Golgi network (TGN) to sites of AQP2 phosphorylation. PLEKHA8 plays a pivotal role in the synthesis of complex glycosphingolipids by mediating non-vesicular transport of glucosylceramide (GlcCer) from the TGN to the plasma membrane. Its function depends on binding both phosphatidylinositol 4-phosphate (PIP) and ARF1, which are essential for its GlcCer transfer ability. Beyond trafficking functions, PLEKHA8 is required for primary cilium formation and membrane tubulation, making it an important target for diverse cellular studies .

The protein is also known by several alternative names including Phosphatidylinositol-four-phosphate adapter protein 2 (FAPP-2), Phosphoinositol 4-phosphate adapter protein 2 (hFAPP2), and Serologically defined breast cancer antigen NY-BR-86, reflecting its various functions and contexts in which it has been studied .

How does PLEKHA8 relate to oncogenic pathways in cancer research?

Recent research has established PLEKHA8 as an emerging oncogene with significant implications in cancer biology. Initially characterized as a membrane trafficking protein, PLEKHA8 has now been implicated in both colorectal and liver cancer progression. Studies reveal that PLEKHA8 enhances the Wnt/β-catenin pathway, a critical signaling cascade in oncogenesis .

Furthermore, the pseudogene-derived long non-coding RNA PLEKHA8P1 has been shown to promote tumor progression in hepatocellular carcinoma (HCC). Experimental validation indicates that the PLEKHA8P1/PLEKHA8 pair confers oncogenic properties through enhancing cell proliferation, migration/invasion, and wound healing. Particularly noteworthy is their role in potentially enhancing HCC resistance to 5-fluorouracil (5-FU), a commonly used chemotherapeutic agent . These findings highlight the importance of studying PLEKHA8 in cancer research contexts, particularly for understanding chemoresistance mechanisms.

What are the critical parameters to evaluate when selecting a PLEKHA8 antibody?

When selecting a PLEKHA8 antibody for research applications, several critical parameters must be evaluated:

• Antibody Specificity: Confirm the antibody recognizes the intended PLEKHA8 epitope with minimal cross-reactivity to other proteins, particularly related family members.

• Host Species and Type: Consider whether a polyclonal (broader epitope recognition) or monoclonal (specific epitope recognition) antibody is appropriate for your application. Commercial options include rabbit-derived polyclonal antibodies with verified human reactivity .

• Target Region: Verify which region of PLEKHA8 the antibody recognizes. For example, some antibodies target amino acids 1-300 of the human PLEKHA8 protein .

• Conjugation: Determine if a conjugated antibody (e.g., FITC-conjugated) is needed for direct detection, or if an unconjugated primary antibody will be used with secondary detection methods .

• Validated Applications: Confirm the antibody has been validated for your specific application (ELISA, Western blot, immunofluorescence, etc.) .

• Storage and Stability: Check recommended storage conditions (typically -20°C or -80°C long-term) and shelf life to ensure experimental consistency .

What methodologies ensure proper validation of PLEKHA8 antibodies?

Proper validation of PLEKHA8 antibodies requires a multi-faceted approach to ensure specificity and reproducibility:

• Western Blot Analysis: Confirm a single band at the expected molecular weight (~58 kDa for full-length human PLEKHA8). Multiple bands may indicate degradation products or non-specific binding.

• Positive and Negative Controls: Include tissue or cell lines known to express or lack PLEKHA8. HEK-293 cells are commonly used for recombinant PLEKHA8 expression as positive controls .

• Knockdown/Knockout Validation: Use siRNA or CRISPR/Cas9 techniques to create PLEKHA8-deficient samples and confirm antibody signal reduction. PLEKHA8 knockdown models have been successfully created using antisense oligonucleotides (ASOs) in HCC cell lines .

• Peptide Competition Assay: Pre-incubate the antibody with purified PLEKHA8 protein or peptide; this should abolish specific staining patterns.

• Orthogonal Method Verification: Correlate protein detection with mRNA expression using RT-PCR or RNA-seq.

• Cross-Species Reactivity Testing: If conducting comparative studies, verify antibody reactivity across required species (human, mouse, etc.).

How can PLEKHA8 antibodies be optimized for subcellular localization studies?

Optimizing PLEKHA8 antibodies for subcellular localization requires careful attention to fixation, permeabilization, and detection methods:

• Fixation Protocol Selection:

  • For preserving Golgi structures, 4% paraformaldehyde (10-15 minutes at room temperature) is recommended

  • Avoid methanol fixation which can disrupt membrane structures where PLEKHA8 localizes

• Permeabilization Optimization:

  • Use 0.1-0.2% Triton X-100 for balanced permeabilization

  • For detailed Golgi studies, consider gentler permeabilization with 0.1% saponin

• Antibody Concentration Titration:

  • Begin with 1:100-1:500 dilution range for commercial antibodies

  • Perform a dilution series to identify optimal signal-to-noise ratio

• Co-staining Considerations:

  • Pair PLEKHA8 antibody with established Golgi markers (GM130, TGN46) to confirm localization

  • Use different fluorophores with minimal spectral overlap to avoid bleed-through

• Detection Enhancement:

  • Employ tyramide signal amplification for detecting low abundance PLEKHA8

  • Consider directly conjugated antibodies (e.g., FITC-conjugated) for reduced background

• Imaging Parameters:

  • Use confocal microscopy with appropriate z-stack sampling for three-dimensional Golgi structure

  • Super-resolution techniques (STED, STORM) can provide detailed localization within Golgi subdomains

What are effective approaches for analyzing PLEKHA8 expression in cancer tissue samples?

Analyzing PLEKHA8 expression in cancer tissue samples requires specialized approaches for accurate quantification and interpretation:

• Immunohistochemistry (IHC) Protocol Optimization:

  • Antigen retrieval: Test citrate buffer (pH 6.0) and EDTA buffer (pH 9.0) to determine optimal epitope exposure

  • Blocking: Extended blocking (2+ hours) with 5-10% normal serum from secondary antibody host species

  • Antibody incubation: Overnight at 4°C with optimized dilution factor

• Tissue Microarray (TMA) Analysis:

  • Include matched normal/tumor pairs when possible

  • Incorporate multiple tumor cores (3+) per case to account for heterogeneity

  • Include known positive controls (e.g., colorectal or liver cancer tissues with confirmed PLEKHA8 expression)

• Scoring Systems for PLEKHA8 Expression:

  Score	Staining Intensity	Percentage of Positive Cells
  0	Negative	<5%
  1	Weak	5-25%
  2	Moderate	26-50%
  3	Strong	51-75%
  4	Very Strong	>75%

• Correlation with Clinical Parameters:

  • Analyze PLEKHA8 expression in relation to tumor stage, grade, and patient survival

  • Compare with expression of PLEKHA8P1 (pseudogene) for comprehensive analysis

• Multiplexed Analysis:

  • Consider multiplex immunofluorescence to simultaneously detect PLEKHA8 with Wnt/β-catenin pathway markers

  • Correlate with markers of chemoresistance when studying treatment-resistant tumors

How can researchers design experiments to investigate PLEKHA8's role in chemoresistance?

Investigating PLEKHA8's role in chemoresistance requires a systematic experimental approach:

• Cell Line Model Selection:

  • Use established chemoresistant cell lines (e.g., HCC cell lines with 5-FU resistance)

  • Include FT3-7 cells, which have been validated for PLEKHA8/PLEKHA8P1 chemoresistance studies

  • Create isogenic pairs of chemosensitive and chemoresistant derivatives

• PLEKHA8 Modulation Approaches:

  • Knockdown: Use ASOs, which have successfully reduced PLEKHA8P1 expression in previous studies

  • Overexpression: Transfect with PLEKHA8 expression vectors (full-length or domain-specific constructs)

  • CRISPR/Cas9: Generate complete knockouts for comprehensive functional analysis

• Chemosensitivity Assay Design:

  • Determine IC50 values for relevant chemotherapeutics (5-FU, cisplatin, etc.)

  • Measure cell viability using multiple methods (CCK8 assay, colony formation assay)

  • Assess cell cycle distribution and apoptosis by flow cytometry following chemotherapy exposure

• Pathway Analysis:

  • Evaluate Wnt/β-catenin pathway activation (potentially regulated by PLEKHA8)

  • Analyze expression of known chemoresistance markers in relation to PLEKHA8 levels

  • Examine lipid composition changes, given PLEKHA8's role in lipid transport

• In Vivo Validation:

  • Develop xenograft models with PLEKHA8-modulated cells

  • Assess tumor growth and response to chemotherapy

  • Analyze tumor tissue for molecular and histological changes

What methodologies can resolve contradictory results in PLEKHA8 antibody-based experiments?

When facing contradictory results in PLEKHA8 antibody-based experiments, researchers should implement the following methodologies to resolve discrepancies:

• Antibody Validation Revisiting:

  • Compare results from multiple antibodies targeting different PLEKHA8 epitopes

  • Verify antibody lot-to-lot consistency through standardized positive controls

  • Reconfirm specificity using knockout/knockdown controls or peptide competition assays

• Technical Replication Strategy:

  • Systematically vary antibody concentrations (1:50 to 1:1000 dilution series)

  • Test multiple detection methods (chemiluminescence, fluorescence-based)

  • Compare different blocking reagents to minimize non-specific binding

• Sample Preparation Optimization:

  • Test multiple lysis buffers to ensure complete extraction of membrane-associated PLEKHA8

  • For immunohistochemistry, compare different fixation methods and antigen retrieval protocols

  • Consider native versus denatured conditions for epitope accessibility

• Isoform and Post-translational Modification Analysis:

  • Determine if antibodies detect specific PLEKHA8 isoforms or modification states

  • Use phospho-specific antibodies if phosphorylation affects detection

  • Consider the impact of protein-protein interactions on epitope masking

• Independent Verification Methods:

  • Corroborate antibody-based results with mass spectrometry

  • Use tagged recombinant PLEKHA8 expression (His-tag, Strep-tag) as alternative detection method

  • Employ RNA-based detection methods (qRT-PCR, RNA-seq) to validate protein-level findings

How can researchers investigate the interaction between PLEKHA8 and its pseudogene PLEKHA8P1?

Investigating the interaction between PLEKHA8 and its pseudogene PLEKHA8P1 requires specialized approaches that address the unique relationship between coding genes and their pseudogene-derived lncRNAs:

• Expression Correlation Analysis:

  • Perform qRT-PCR to quantify both PLEKHA8 and PLEKHA8P1 expression across tissue panels

  • Calculate Pearson/Spearman correlation coefficients to determine expression relationship

  • Use public databases (TCGA LIHC dataset) for in silico validation of expression patterns

• Selective Knockdown Studies:

  • Design ASOs specifically targeting PLEKHA8P1 (avoid cross-targeting PLEKHA8)

  • Create PLEKHA8 knockdown without affecting PLEKHA8P1

  • Perform reciprocal knockdowns to detect regulatory relationships

• Molecular Interaction Assessment:

  • Conduct RNA immunoprecipitation (RIP) to detect if PLEKHA8P1 binds to proteins regulating PLEKHA8

  • Use RNA pulldown assays to identify proteins binding to PLEKHA8P1

  • Employ chromatin isolation by RNA purification (ChIRP) to determine genomic binding sites of PLEKHA8P1

• Competitive Endogenous RNA (ceRNA) Analysis:

  • Identify shared microRNA binding sites between PLEKHA8 and PLEKHA8P1

  • Perform luciferase reporter assays to verify ceRNA functionality

  • Conduct rescue experiments to confirm molecular sponging mechanisms

• Functional Impact Assessment:

  • Compare phenotypic effects of individual versus combined knockdowns on:

    • Cell proliferation (CCK8 assay, colony formation)

    • Cell cycle progression (flow cytometry)

    • Apoptosis (Annexin V/PI staining)

    • Migration/invasion capability

    • Chemoresistance (5-FU sensitivity)

What techniques can elucidate PLEKHA8's role in primary cilium formation?

Elucidating PLEKHA8's role in primary cilium formation requires specialized techniques spanning microscopy, biochemistry, and genetic approaches:

• Advanced Imaging Methodologies:

  • Immunofluorescence using acetylated α-tubulin and γ-tubulin to mark ciliary axoneme and basal body

  • Live-cell imaging with fluorescently tagged PLEKHA8 to track protein dynamics during ciliogenesis

  • Super-resolution microscopy (SIM, STED) to precisely localize PLEKHA8 within ciliary subdomains

  • Transmission electron microscopy for ultrastructural analysis of cilia in PLEKHA8-depleted cells

• Temporal Analysis of PLEKHA8 During Ciliogenesis:

  • Synchronize cells through serum starvation to induce primary cilium formation

  • Collect time-course samples to monitor PLEKHA8 localization relative to ciliary markers

  • Use FRAP (Fluorescence Recovery After Photobleaching) to measure PLEKHA8 mobility at the ciliary base

• Lipid Transport Analysis:

  • Track fluorescently labeled lipids (BODIPY-GlcCer) in PLEKHA8-depleted versus control cells

  • Analyze lipid raft formation at the ciliary membrane using detergent-resistant membrane fractionation

  • Measure PIP and ARF1 availability at ciliary bases in relation to PLEKHA8 activity

• Protein-Protein Interaction Network Mapping:

  • Identify PLEKHA8-interacting proteins in ciliated cells using proximity labeling (BioID, APEX)

  • Perform co-immunoprecipitation of PLEKHA8 followed by mass spectrometry

  • Validate key interactions with known ciliary transport proteins through traditional co-IP or FRET

• PLEKHA8 Domain-Function Analysis:

  • Generate domain deletion mutants to identify regions required for ciliary localization

  • Create phosphoinositide-binding deficient mutants to test PIP-dependency of ciliary function

  • Employ optogenetic tools to achieve temporal control of PLEKHA8 recruitment to pre-ciliary structures